Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

Table 2

DCR of patients with osteosarcoma using anlotinib as first-line therapy, second-line therapy, or beyond second-line therapy.

Treatment line	DCR
	Anlotinib	Anlotinib plus chemotherapy	Total
First line	0 (0/0)	0 (0/2)	0 (0/2)
Second line	50 (2/4)	75 (3/4)	63 (5/8)
Beyond second line	67 (2/3)	0 (0/0)	67 (2/3)
Total	57 (4/7)	50 (3/6)	54 (7/13)